Figure 3 from Phase I Study of Simlukafusp Alfa (Fap-Il2v) with or Without Atezolizumab in Japanese Patients with Advanced Solid Tumors
crossref（2024）
摘要
Summary of efficacy with simlukafusp alfa. Best overall response in each patient is presented in parentheses at the end of the bar. NE, not evaluable; PD, progressive disease; RPC, renal pelvis cancer; SD, stable disease.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn